Nephrotic Syndrome Treatment Market Size, Share, By Drugs (Sodium Restriction Drugs, Fluid Restriction Drugs, Loop Diuretics, Angiotensin-Converting Enzyme Inhibitor, and Others), Type (Primary Nephrotic Syndrome, Secondary Nephrotic Syndrome, Congenital Nephrotic Syndrome, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy), and Region - Trends, Analysis, and Forecast till 2035

• Mallinckrodt company
• Novartis AG
• Cerium Pharmaceuticals, Inc.
• Chugai Pharmaceutical Co., Ltd.
• Aurinia Pharmaceuticals Inc.
• Sanofi
• Regeneron Pharmaceuticals Inc.
• Asahi Kasei Corporation
• Eli Lilly and Company
• Merck & Co., Inc.
• Pharmaceuticals, Inc.
• Baxter International Inc.

Recent News:

• Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, partnered with the University of Michigan on the Nephrotic Syndrome Study Network (NEPTUNE) Match project in November 2024. In partnership with Vera Therapeutics, NEPTUNE Match will inform potential participants about the PIONEER study.
• A new study published in Science Translational Medicine, researchers at the University of Bristol have shown that just one dose of gene therapy targeting cells in the kidney called podocytes has the potential to cure steroid-resistant nephrotic syndrome in August 2023. The research team proposed that gene therapy could be applied to correct these faults. The most common fault is in one gene that codes for a protein called podocin, which is essential for the function of cells called podocytes (a critical part of the kidney’s filtration unit).